Euroopa Liit - eesti - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - riniit, allergiline, hooajaline - nina preparaadid - hooajalise allergilise riniidi sümptomaatiline ravi, kui sellega kaasneb ninakinnisus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

viatris healthcare limited - fenofibraadi, simvastatin - düslipideemiad - lipiidi modifitseerivad ained - cholib on näidustatud primaarse hüperkolesteroleemiaga ja segatüüpi et triglütseriidide suur sisaldus ja hdl kolesterooli kui ldl kolesterooli piisavalt kontrollida vastava annuse täiskasvanud patsientidel kardiovaskulaarse riskiga simvastatiini monoteraapiaga.

Euroopa Liit - eesti - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporoos, postmenopausis - narkootikumid luuhaiguste raviks - menopausijärgse osteoporoosi ravi d-vitamiini puudulikkusega patsientidel. fosavance vähendab lülisamba ja puusaluu murrud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

actavis group ptc ehf - imatiniib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. mõju imatinib tulemuste kohta luuüdi siirdamine ei ole kindlaks. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kogemus imatinib patsientidel mds/mpd seotud pdgfr geeni taas-kord on väga piiratud. puuduvad kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amneal pharma europe ltd - levodopa, carbidopa - parkinsoni tõbi - parkinsoni tõve ravimid - parkinsoni tõvega täiskasvanud patsientide sümptomaatiline ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

recordati ireland ltd - silodosiin - eesnäärme hüperplaasia - uroloogilised ravimid - healoomulise eesnäärme hüperplaasia (bph) sümptomite ravi..

Euroopa Liit - eesti - EMA (European Medicines Agency)

recordati ireland ltd - silodosiin - eesnäärme hüperplaasia - uroloogilised ravimid - healoomulise eesnäärme hüperplaasia (bph) sümptomite ravi..

Euroopa Liit - eesti - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporoos, postmenopausis - narkootikumid luuhaiguste raviks - menopausijärgse osteoporoosi ravi d-vitamiini puudulikkusega patsientidel. vantavo vähendab lülisamba ja puusaluu murrud. ravi postmenopausis osteoporoosi patsientidel, kes ei saanud vitamiin-d täiendamine ja on risk vitamiin-d puudulikkus. vantavo vähendab lülisamba ja puusaluu murrud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v. - fentanüül - pain; cancer - valuvaigistid - effentora on näidustatud läbimurdevalu (btp) raviks vähiga täiskasvanutel, kes saavad kroonilise vähivalu korral juba hooldustopioidset ravi. btp on mööduv valu ägenemine, mis tekib taustal muul moel kontrollitud püsiva valu. saavate patsientide hooldus opioidide ravi on need, kes on võttes vähemalt 60 mg suukaudset morfiini päevas, vähemalt 25 mikrogrammi transdermaalset fentanüüli tunnis, vähemalt 30 mg oksükodoon päevas, vähemalt 8 mg suukaudse hüdromorfoon iga päev või equianalgesic annus teise opioidi ühe nädala jooksul või kauem,.